Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06016088 · ClinicalTrials.gov registry record · Phase 1
A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection
A Phase 1 study of Pseudomonas Aeruginosa and Cystic Fibrosis Lung, sponsored by Respirion Pharmaceuticals Pty.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
- 20
- Study locations
NCT06016088: Recruiting Phase 1 study of Pseudomonas Aeruginosa and Cystic Fibrosis Lung, sponsored by Respirion Pharmaceuticals Pty.
NCT06016088 is a Phase 1 study of Pseudomonas Aeruginosa and Cystic Fibrosis Lung that is actively recruiting participants, run by Respirion Pharmaceuticals Pty. The registered enrollment target is 72 participants, below the 102-participant average among 4 other Pseudomonas Aeruginosa trials with a reported enrollment target (29% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06016088, a Phase 1 study of Pseudomonas Aeruginosa and Cystic Fibrosis Lung, is actively recruiting participants, sponsored by Respirion Pharmaceuticals Pty.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
- 20
- Study locations
Study Summary
A double-blind, active-controlled, multiple-ascending dose, safety study of aerosolized RSP-1502 in subjects with cystic fibrosis Pseudomonas aeruginosa lung infection.
Conditions Studied
Interventions
- DRUG RSP-1502
- DRUG Tobramycin inhalation solution
Study Locations (20)
California
- Center for Cystic Fibrosis at Keck Medical Center of USC - Los Angeles
- Stanford University Medical Center - Palo Alto
Ohio
- Rainbow Babies and Children's Hospital / University Hospitals Cleveland Medical Center - Cleveland
- Nationwide Children's Hospital - Columbus
New South Wales
- Royal Prince Albert Hospital - Camperdown
- Westmead Hospital - Westmead
Queensland
- Queensland Children's Hospital - Brisbane
- The Prince Charles Hospital - Brisbane
Victoria
- The Alfred Hospital - Melbourne
- The Royal Children's Hospital - Parkville
Arizona
- Tucson Cystic Fibrosis Center - Tucson
Georgia
- Augusta University - Augusta
Illinois
- The Cystic Fibrosis Institute - Northfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2024-04-01 |
| Est. Completion | 2026-06 |
| Phase | Phase 1 |
What NCT06016088 shows while recruiting
NCT06016088 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 102-participant average among 4 other Pseudomonas Aeruginosa trials with a reported enrollment target (29% lower).
The record links to 3 conditions, with Pseudomonas Aeruginosa appearing as the primary indexed condition, and to 2 interventions - of which RSP-1502 is the first listed.
NCT06016088 names 20 study sites across 15 states, led by California, Ohio, New South Wales.
Frequently Asked Questions
What is clinical trial NCT06016088 about?
NCT06016088 is a clinical study titled "A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection". A double-blind, active-controlled, multiple-ascending dose, safety study of aerosolized RSP-1502 in subjects with cystic fibrosis Pseudomonas aeruginosa lung infection.
What is the current status of trial NCT06016088?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2024-04-01. Estimated completion is 2026-06.
What conditions does trial NCT06016088 study?
This clinical trial studies the following conditions: Pseudomonas Aeruginosa, Cystic Fibrosis Lung, Respiratory Infections, Recurrent, Chronic.
What interventions are being tested in trial NCT06016088?
The interventions under investigation include: RSP-1502 (DRUG), Tobramycin inhalation solution (DRUG).
Who is sponsoring clinical trial NCT06016088?
This trial is sponsored by Respirion Pharmaceuticals Pty, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06016088 being conducted?
This trial has 20 study locations across Arizona, California, Georgia, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pseudomonas Aeruginosa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PMT for MDRO Decolonization
RECRUITING · Phase 2
-
Pathobiomes in Gut of Critically Ill Patients
RECRUITING
-
The Carrier Rates of Pseudomonas Aeruginosa in Family Members of Children With Cystic Fibrosis
COMPLETED
-
Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa Infection
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI